<DOC>
	<DOCNO>NCT01834664</DOCNO>
	<brief_summary>This Study Single arm , Single Centre trial study safety efficacy bone marrow derive autologous mononuclear cell ( 100 million per dose ) study enrollment duration 36 month sample size 100 patient treat ( 15 year age ) cerebral palsy India . Primary outcome measure improvement walk ability kinetic gait pattern .</brief_summary>
	<brief_title>Safety Efficacy Bone Marrow Derived Autologous Cells Treatment Cerebral Palsy Subjects Above 15 Years</brief_title>
	<detailed_description>Cerebral Palsy common cause Disability India south East Asia . This Study devise quantify safety efficacy bone marrow derive autologous mononuclear cell ( 100 million per dose ) study enrolment duration 36 month sample size 100 patient treat ( 15 year age ) cerebral palsy , India . Primary outcome measure improvement walk ability kinetic gait pattern per various clinical scale also change brain .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Genetic Diseases , Inborn</mesh_term>
	<criteria>Subject age 15 year diagnosis Cerebral Palsy . Regional Nerve damage show Magnetic Resonance Imaging ( MRI ) Patient suffer cerebral palsy due prenatal postnatal cause , Willing undergo Bone Marrow derive autologous stem cell therapy . Able Comprehend give write informed consent form study willing come hospital follow visit per protocol requirement History meningitis , meningoencephalitis , epilepsy life threaten allergic immune mediate reaction Hemodynamically unstable patient history concurrent autoimmune disease acute episode Guillain barre syndrome peripheral Muscular dystrophy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Ataxic Infantile Cerebral Palsy stem cell therapy</keyword>
</DOC>